Xue H, Wei F
Ann Hematol. 2024; 103(11):4351-4362.
PMID: 38900304
PMC: 11534828.
DOI: 10.1007/s00277-024-05843-4.
Wei R, Cao Y, Wu H, Liu X, Jiang M, Luo X
Aging (Albany NY). 2023; 15(16):8220-8236.
PMID: 37606987
PMC: 10497005.
DOI: 10.18632/aging.204965.
Guimaraes P, Figueroa-Espada C, Riley R, Gong N, Xue L, Sewastianik T
Proc Natl Acad Sci U S A. 2023; 120(25):e2215711120.
PMID: 37310997
PMC: 10288566.
DOI: 10.1073/pnas.2215711120.
Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M
Pharmaceuticals (Basel). 2023; 16(3).
PMID: 36986514
PMC: 10056051.
DOI: 10.3390/ph16030415.
Oudaert I, Van der Vreken A, Maes A, de Bruyne E, de Veirman K, Vanderkerken K
Exp Hematol Oncol. 2022; 11(1):49.
PMID: 36050788
PMC: 9438316.
DOI: 10.1186/s40164-022-00303-z.
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.
Drandi D, Decruyenaere P, Ferrante M, Offner F, Vandesompele J, Ferrero S
Diagnostics (Basel). 2022; 12(4).
PMID: 35454017
PMC: 9028641.
DOI: 10.3390/diagnostics12040969.
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
Swamydas M, Murphy E, Ignatz-Hoover J, Malek E, Driscoll J
J Hematol Oncol. 2022; 15(1):17.
PMID: 35172851
PMC: 8848665.
DOI: 10.1186/s13045-022-01234-2.
Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma.
Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S
Int J Mol Sci. 2021; 22(16).
PMID: 34445745
PMC: 8396675.
DOI: 10.3390/ijms22169039.
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?.
Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C
Cancers (Basel). 2021; 13(14).
PMID: 34298680
PMC: 8303391.
DOI: 10.3390/cancers13143466.
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E
Int J Mol Sci. 2021; 22(9).
PMID: 33923357
PMC: 8123209.
DOI: 10.3390/ijms22094462.
Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma.
Fernando R, de Carvalho F, Leme A, Colleoni G
Front Oncol. 2021; 11:563384.
PMID: 33833982
PMC: 8021918.
DOI: 10.3389/fonc.2021.563384.
The "Vesicular Intelligence" Strategy of Blood Cancers.
Forte D, Barone M, Palandri F, Catani L
Genes (Basel). 2021; 12(3).
PMID: 33805807
PMC: 7999060.
DOI: 10.3390/genes12030416.
Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo.
Clark K, Hewett D, Panagopoulos V, Plakhova N, Opperman K, Bradey A
Cancers (Basel). 2020; 12(8).
PMID: 32756430
PMC: 7464474.
DOI: 10.3390/cancers12082149.
Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?.
Xu S, Lam K
Cancers (Basel). 2020; 12(4).
PMID: 32340409
PMC: 7226350.
DOI: 10.3390/cancers12041045.
Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor.
Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A
Cancers (Basel). 2020; 12(2).
PMID: 32069911
PMC: 7072437.
DOI: 10.3390/cancers12020440.
Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders.
Crippa S, Santi L, Bosotti R, Porro G, Bernardo M
J Clin Med. 2019; 9(1).
PMID: 31861268
PMC: 7019991.
DOI: 10.3390/jcm9010002.
A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schurch C, Rasche L, Frauenfeld L, Weinhold N, Fend F
Virchows Arch. 2019; 476(3):337-351.
PMID: 31848687
DOI: 10.1007/s00428-019-02725-3.
The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression.
Gilad N, Zukerman H, Pick M, Gatt M
Oncotarget. 2019; 10(52):5480-5491.
PMID: 31534632
PMC: 6739209.
DOI: 10.18632/oncotarget.27190.
Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies.
Cominal J, da Costa Cacemiro M, Pinto-Simoes B, Kolb H, Malmegrim K, Attie de Castro F
Stem Cells Int. 2019; 2019:6854080.
PMID: 31281380
PMC: 6589251.
DOI: 10.1155/2019/6854080.
Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.
Hathi D, Engelbach J, Hillengass J, Veis D, Achilefu S, Garbow J
NMR Biomed. 2019; 32(9):e4122.
PMID: 31206946
PMC: 6692195.
DOI: 10.1002/nbm.4122.